Literature DB >> 1858780

Agranulocytosis caused by ticlopidine and its mechanism.

K Ono1, K Kurohara, M Yoshihara, Y Shimamoto, M Yamaguchi.   

Abstract

A 75-year-old female patient with agranulocytosis caused by ticlopidine is reported. She took the drug at 200 mg/day for 30 days to prevent recurrence of cerebral infarction. The leukocyte count at the nadir was 500/microliters on the 34th day since she started to take the drug. Complete recovery of her peripheral leukocytes came 12 days after its withdrawal. In this patient, mechanisms of ticlopidine-caused agranulocytosis were studied. The lymphocyte stimulation test using ticlopidine was negative. In the culture of marrow cells depleted of lymphocytes, ticlopidine directly inhibited the CFU-C in a dose-dependent manner. Neither the serum on the day of admission nor the T-lymphocytes pre-cultured with ticlopidine had any effect on the CFU-C. The lymphocyte stimulation test is useless in an attempt to find the causal drug in agranulocytosis if it is caused in a directly toxic manner. Agranulocytosis caused by ticlopidine is rare, but careful follow-up is necessary in the case of patients on the drug because there are some whose marrow cells are very sensitive to it.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1858780     DOI: 10.1002/ajh.2830370405

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  11 in total

1.  Hematologic dyscrasia associated with ticlopidine therapy: evidence for causality.

Authors:  F L Paradiso-Hardy; C M Angelo; K L Lanctôt; E A Cohen
Journal:  CMAJ       Date:  2000-11-28       Impact factor: 8.262

Review 2.  Antiplatelet Therapy in Acute Coronary Syndrome.

Authors:  Kerry Layne; Albert Ferro
Journal:  Eur Cardiol       Date:  2017-08

3.  Comparison of in vitro metabolism of ticlopidine by human cytochrome P450 2B6 and rabbit cytochrome P450 2B4.

Authors:  Jyothi C Talakad; Manish B Shah; Gregory S Walker; Cathie Xiang; James R Halpert; Deepak Dalvie
Journal:  Drug Metab Dispos       Date:  2010-12-14       Impact factor: 3.922

Review 4.  Ticlopidine. A review of its pharmacology, clinical efficacy and tolerability in the prevention of cerebral ischaemia and stroke.

Authors:  S Noble; K L Goa
Journal:  Drugs Aging       Date:  1996-03       Impact factor: 3.923

5.  Natural killing activity is associated with progression of gastric cancer.

Authors:  K Ono; Y Imazono; T Misawa; J Nishimura; H Nawata
Journal:  J Clin Immunol       Date:  1995-07       Impact factor: 8.317

Review 6.  Adverse haematological effects of ticlopidine. Prevention, recognition and management.

Authors:  B B Love; J Biller; M Gent
Journal:  Drug Saf       Date:  1998-08       Impact factor: 5.606

7.  Formation, reactivity, and antiplatelet activity of mixed disulfide conjugates of clopidogrel.

Authors:  Haoming Zhang; D Adam Lauver; Benedict R Lucchesi; Paul F Hollenberg
Journal:  Mol Pharmacol       Date:  2013-01-24       Impact factor: 4.436

8.  Clopidogrel-induced neutropenia after coronary stenting: is cilostazol a good alternative?

Authors:  Massimo Montalto; Italo Porto; Antonella Gallo; Claudia Camaioni; Roberta Della Bona; Antonio Grieco; Filippo Crea; Raffaele Landolfi
Journal:  Int J Vasc Med       Date:  2011-08-11

Review 9.  Alternative testing systems for evaluating noncarcinogenic, hematologic toxicity.

Authors:  R E Parchment
Journal:  Environ Health Perspect       Date:  1998-04       Impact factor: 9.031

Review 10.  Personalized antiplatelet therapy with P2Y12 receptor inhibitors: benefits and pitfalls.

Authors:  Max-Paul Winter; Marek Koziński; Jacek Kubica; Daniel Aradi; Jolanta M Siller-Matula
Journal:  Postepy Kardiol Interwencyjnej       Date:  2015-01-12       Impact factor: 1.426

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.